nach oben

Erschienen in:

01.10.2015 | Original Article

Consensus and differences in primary radiotherapy for localized and locally advanced prostate cancer in Switzerland

A survey on patterns of practice

verfasst von: Cédric M. Panje, M.D., Alan Dal Pra, M.D., Thomas Zilli, M.D., Daniel R. Zwahlen, M.D., M.B.A., Alexandros Papachristofilou, M.D., Fernanda G. Herrera, M.D., Oscar Matzinger, M.D. P.D., Ludwig Plasswilm, M.D., Paul Martin Putora, M.D. Ph.D. M.A.

Erschienen in: Strahlentherapie und Onkologie | Ausgabe 10/2015

Einloggen, um Zugang zu erhalten

Abstract

Introduction

External beam radiotherapy (EBRT), with or without androgen deprivation therapy (ADT), is an established treatment option for nonmetastatic prostate cancer. Despite high-level evidence from several randomized trials, risk group stratification and treatment recommendations vary due to contradictory or inconclusive data, particularly with regard to EBRT dose prescription and ADT duration. Our aim was to investigate current patterns of practice in primary EBRT for prostate cancer in Switzerland.

Materials and methods

Treatment recommendations on EBRT and ADT for localized and locally advanced prostate cancer were collected from 23 Swiss radiation oncology centers. Written recommendations were converted into center-specific decision trees, and analyzed for consensus and differences using a dedicated software tool. Additionally, specific radiotherapy planning and delivery techniques from the participating centers were assessed.

Results

The most commonly prescribed radiation dose was 78 Gy (range 70–80 Gy) across all risk groups. ADT was recommended for intermediate-risk patients for 6 months in over 80 % of the centers, and for high-risk patients for 2 or 3 years in over 90 % of centers. For recommendations on combined EBRT and ADT treatment, consensus levels did not exceed 39 % in any clinical scenario. Arc-based intensity-modulated radiotherapy (IMRT) is implemented for routine prostate cancer radiotherapy by 96 % of the centers.

Conclusion

Among Swiss radiation oncology centers, considerable ranges of radiotherapy dose and ADT duration are routinely offered for localized and locally advanced prostate cancer. In the vast majority of cases, doses and durations are within the range of those described in current evidence-based guidelines.

Siegel R, Ma J, Zou Z, Jemal A (2014) Cancer statistics, 2014. CA Cancer J Clin 64:9–29. doi:10.3322/caac.21208CrossRefPubMed

Wenz F, Martin T, Bohmer D, Martens S, Sedlmayer F, Wirth M, Miller K, Heidenreich A, Schrader M, Hinkelbein W, Wiegel T (2010) The German S3 guideline prostate cancer: aspects for the radiation oncologist. Strahlenther Onkol 186:531–534. doi:10.1007/s00066-010-2193-3CrossRefPubMed

Mohler JL, Kantoff PW, Armstrong AJ, Bahnson RR, Cohen M, D’Amico AV, Eastham JA, Enke CA, Farrington TA, Higano CS, Horwitz EM, Kane CJ, Kawachi MH, Kuettel M, Kuzel TM, Lee RJ, Malcolm AW, Miller D, Plimack ER, Pow-Sang JM, Raben D, Richey S, Roach M, III, Rohren E, Rosenfeld S, Schaeffer E, Small EJ, Sonpavde G, Srinivas S, Stein C, Strope SA, Tward J, Shead DA, Ho M (2014) Prostate cancer, version 2.2014. J Natl Compr Cancer Netw 12:686–718

Heidenreich A, Bastian PJ, Bellmunt J, Bolla M, Joniau S, van der Kwast T, Mason M, Matveev V, Wiegel T, Zattoni F, Mottet N (2014) EAU guidelines on prostate cancer. part 1: screening, diagnosis, and local treatment with curative intent-update 2013. Eur Urol 65:124–137. doi:10.1016/j.eururo.2013.09.046CrossRefPubMed

Bolla M, de Reijke TM, Van Tienhoven G, Van den Bergh AC, Oddens J, Poortmans PM, Gez E, Kil P, Akdas A, Soete G, Kariakine O, van der Steen-Banasik EM, Musat E, Pierart M, Mauer ME, Collette L, Group ERO, genito-urinary tract cancer G (2009) Duration of androgen suppression in the treatment of prostate cancer. N Engl J Med 360:2516–2527. doi:10.1056/NEJMoa0810095CrossRefPubMed

Horwitz EM, Bae K, Hanks GE, Porter A, Grignon DJ, Brereton HD, Venkatesan V, Lawton CA, Rosenthal SA, Sandler HM, Shipley WU (2008) Ten-year follow-up of radiation therapy oncology group protocol 92-02: a phase III trial of the duration of elective androgen deprivation in locally advanced prostate cancer. J Clin Oncol 26:2497–2504. doi:10.1200/JCO.2007.14.9021CrossRefPubMed

D’Amico AV, Denham JW, Bolla M, Collette L, Lamb DS, Tai KH, Steigler A, Chen MH (2007) Short- vs long-term androgen suppression plus external beam radiation therapy and survival in men of advanced age with node-negative high-risk adenocarcinoma of the prostate. Cancer 109:2004–2010. doi:10.1002/cncr.22628CrossRefPubMed

Dearnaley DP, Jovic G, Syndikus I, Khoo V, Cowan RA, Graham JD, Aird EG, Bottomley D, Huddart RA, Jose CC, Matthews JH, Millar JL, Murphy C, Russell JM, Scrase CD, Parmar MK, Sydes MR (2014) Escalated-dose versus control-dose conformal radiotherapy for prostate cancer: long-term results from the MRC RT01 randomised controlled trial. Lancet Oncol 15:464–473. doi:10.1016/S1470-2045(14)70040-3CrossRefPubMed

Kuban DA, Tucker SL, Dong L, Starkschall G, Huang EH, Cheung MR, Lee AK, Pollack A (2008) Long-term results of the M. D. Anderson randomized dose-escalation trial for prostate cancer. Int J Radiat Oncol Biol Phys 70:67–74. doi:10.1016/j.ijrobp.2007.06.054CrossRefPubMed

10.

Zietman AL, DeSilvio ML, Slater JD, Rossi CJ, Jr, Miller DW, Adams JA, Shipley WU (2005) Comparison of conventional-dose vs high-dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate: a randomized controlled trial. JAMA 294:1233–1239. doi:10.1001/jama.294.10.1233CrossRefPubMed

11.

Cahlon O, Hunt M, Zelefsky MJ (2008) Intensity-modulated radiation therapy: supportive data for prostate cancer. Semin Radiat Oncol 1:48–57

12.

Dinan MA, Robinson TJ, Zagar TM, Scales CD, Jr, Curtis LH, Reed SD, Lee WR, Schulman KA (2012) Changes in initial treatment for prostate cancer among Medicare beneficiaries, 1999–2007. Int J Radiat Oncol Biol Phys 82:e781–e786. doi:10.1016/j.ijrobp.2011.11.024PubMedCentralCrossRefPubMed

13.

Poortmans PM, Aarts MJ, Jobsen JJ, Koning CC, Lybeert ML, Struikmans H, Vulto JC, Louwman WJ, Coebergh JW, Koldewijn EL (2011) A population-based study on the utilisation rate of primary radiotherapy for prostate cancer in 4 regions in the Netherlands, 1997–2008. Radiother Oncol 99:207–213. doi:10.1016/j.radonc.2011.05.018CrossRefPubMed

14.

Zaorsky NG, Harrison AS, Trabulsi EJ, Gomella LG, Showalter TN, Hurwitz MD, Dicker AP, Den RB (2013) Evolution of advanced technologies in prostate cancer radiotherapy. Nat Rev Urol 10:565–579. doi:10.1038/nrurol.2013.185CrossRefPubMed

15.

Zapatero A, Lopez-Torrecilla J, Herruzo I, Calvo FA, Investigators SUGp (2013) Practice patterns in the management of prostate cancer in Spain: results from a national survey among radiation oncologists in 2009. Clin Transl Oncol 15:226–232. doi:10.1007/s12094-012-0913-0CrossRefPubMed

16.

Zelefsky MJ, Lee WR, Zietman A, Khalid N, Crozier C, Owen J, Wilson JF (2013) Evaluation of adherence to quality measures for prostate cancer radiotherapy in the United States: results from the Quality Research in Radiation Oncology (QRRO) survey. Pract Radiat Oncol 3:2–8. doi:10.1016/j.prro.2012.01.006PubMedCentralCrossRefPubMed

17.

Nakamura K, Akimoto T, Mizowaki T, Hatano K, Kodaira T, Nakamura N, Kozuka T, Shikama N, Kagami Y (2012) Patterns of practice in intensity-modulated radiation therapy and image-guided radiation therapy for prostate cancer in Japan. Jpn J Clin Oncol 42:53–57. doi:10.1093/jjco/hyr175CrossRefPubMed

18.

Vordermark D, Marold D, Wirth S, Keilholz L, Pfandner K, Schimpke T, Thiel HJ, Willner J, Ziegler K, Guckenberger M, Flentje M (2007) Patterns of care in the radiotherapy of prostate cancer in Northern Bavaria 1998–2000. Strahlenther Onkol 183:314–320. doi:10.1007/s00066-007-1746-6CrossRefPubMed

19.

Putora P, Panje CM, Papachristofilou A, Pra A, Hundsberger T, Plasswilm L (2014) Objective consensus from decision trees. Radiat Oncol 9:270. doi:10.1186/s13014-014-0270-yPubMedCentralCrossRefPubMed

20.

D’Amico AV, Whittington R, Malkowicz SB, Schultz D, Blank K, Broderick GA, Tomaszewski JE, Renshaw AA, Kaplan I, Beard CJ, Wein A (1998) Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 280:969–974CrossRefPubMed

21.

Putora P-M, Blattner BM, Papachristofilou A, Mariotti F, Paoli B, Plasswilm L (2010) Dodes (diagnostic nodes) for guideline manipulation. J Radiat Oncol Inform 2:1–8

22.

Roach M, III, Marquez C, Yuo HS, Narayan P, Coleman L, Nseyo UO, Navvab Z, Carroll PR (1994) Predicting the risk of lymph node involvement using the pre-treatment prostate specific antigen and Gleason score in men with clinically localized prostate cancer. Int J Radiat Oncol Biol Phys 28:33–37CrossRefPubMed

23.

Zelefsky MJ, Kattan MW, Fearn P, Fearon BL, Stasi JP, Shippy AM, Scardino PT (2007) Pretreatment nomogram predicting ten-year biochemical outcome of three-dimensional conformal radiotherapy and intensity-modulated radiotherapy for prostate cancer. Urology 70:283–287. doi:10.1016/j.urology.2007.03.060CrossRefPubMed

24.

Wang D, Ho A, Hamilton AS, Wu XC, Lo M, Fleming S, Goodman M, Thompson T, Owen J (2014) Type and dose of radiotherapy used for initial treatment of non-metastatic prostate cancer. Radiat Oncol 9:47. doi:10.1186/1748-717X-9-47PubMedCentralCrossRefPubMed

25.

Webber C, Brundage MD, Siemens DR, Groome PA (2013) Quality of care indicators and their related outcomes: a population-based study in prostate cancer patients treated with radiotherapy. Radiother Oncol 107:358–365. doi:10.1016/j.radonc.2013.04.017CrossRefPubMed

26.

Poitevin-Chacon A, Hinojosa-Gomez J (2012) Patterns of care of radiotherapy in Mexico. Rep Pract Oncol Radiother 18:57–60. doi:10.1016/j.rpor.2012.09.001PubMedCentralCrossRefPubMed

27.

Goldner G, Sljivic S, Oismueller R, Salinger J, Mittermuller M, Langsenlehner T, Harder W, Kametriser G, Eiter H, Nechvile E (2011) Prostate cancer radiotherapy in Austria: overview on number of patients, intention to treat, and treatment techniques based on data from 2007. Strahlenther Onkol 187:279–283. doi:10.1007/s00066-011-2268-9CrossRefPubMed

28.

Putora PM, Oldenburg J (2013) Swarm-based medicine. J Med Internet Res 15:e207. doi:10.2196/jmir.2452PubMedCentralCrossRefPubMed

29.

Pegurri L, Buglione M, Girelli G, Guarnieri A, Meattini I, Ricardi U, Mangoni M, Gabriele P, Bellavita R, Krengli M, Bonetta A, Cagna E, Bunkheila F, Borghesi S, Signor M, Di Marco A, Bertoni F, Stefanacci M, Gatta R, De Bari B, Magrini SM (2014) Changes in patterns of practice for prostate cancer radiotherapy in Italy 1995–2003. A survey of the Prostate Cancer Study Group of the Italian Radiation Oncology Society. Tumori 100:31–37. doi:10.1700/1430.15812PubMed

30.

Peeters ST, Heemsbergen WD, Koper PC, van Putten WL, Slot A, Dielwart MF, Bonfrer JM, Incrocci L, Lebesque JV (2006) Dose-response in radiotherapy for localized prostate cancer: results of the Dutch multicenter randomized phase III trial comparing 68 Gy of radiotherapy with 78 Gy. J Clin Oncol 24:1990–1996. doi:10.1200/JCO.2005.05.2530CrossRefPubMed

31.

Michalski J, Moughan J, Purdy J, Bosch W, Bahary J, Lau H, Duclos M, Parliament M, Morton G, Hamstra D (2014) Initial results of a phase 3 randomized study of high dose 3DCRT/IMRT versus standard dose 3D-CRT/IMRT in patients treated for localized prostate cancer (RTOG 0126). Int J Radiat Oncol Biol Phys 90:1263CrossRef

32.

Michalski JM, Yan Y, Watkins-Bruner D, Bosch WR, Winter K, Galvin JM, Bahary JP, Morton GC, Parliament MB, Sandler HM (2013) Preliminary toxicity analysis of 3-dimensional conformal radiation therapy versus intensity modulated radiation therapy on the high-dose arm of the Radiation Therapy Oncology Group 0126 prostate cancer trial. Int J Radiat Oncol Biol Phys 87:932–938. doi:10.1016/j.ijrobp.2013.07.041CrossRefPubMed

33.

Sander L, Langkilde NC, Holmberg M, Carl J (2013) MRI target delineation may reduce long-term toxicity after prostate radiotherapy. Acta Oncol doi:10.3109/0284186X.2013.865077

34.

Boda-Heggemann J, Lohr F, Wenz F, Flentje M, Guckenberger M (2011) kV cone-beam CT-based IGRT: a clinical review. Strahlenther Onkol 187:284–291. doi:10.1007/s00066-011-2236-4CrossRefPubMed

35.

Schiller K, Petrucci A, Geinitz H, Schuster T, Specht H, Kampfer S, Duma MN (2014) Impact of different setup approaches in image-guided radiotherapy as primary treatment for prostate cancer. Strahlenther Onkol 190:722–726. doi:10.1007/s00066-014-0629-xCrossRefPubMed

36.

Langsenlehner T, Doller C, Winkler P, Galle G, Kapp KS (2013) Impact of inter- and intrafraction deviations and residual set-up errors on PTV margins. Different alignment techniques in 3D conformal prostate cancer radiotherapy. Strahlenther Onkol 189:321–328. doi:10.1007/s00066-012-0303-0CrossRefPubMed

37.

Payne H, Mason M (2011) Androgen deprivation therapy as adjuvant/neoadjuvant to radiotherapy for high-risk localised and locally advanced prostate cancer: recent developments. Br J Cancer 105:1628–1634. doi:10.1038/bjc.2011.385PubMedCentralCrossRefPubMed

38.

Zapatero A, Guerrero A, Maldonado X, Álvarez A, González San Segundo C, Cabeza Rodríguez M, Macías A, Pedro-Olive A, Casas F, Boladeras A, Martín de Vidales C, Vázquez de la Torre M, Villã S, Calvo FA (2015) Randomized phase III trial (DART 01/05) of androgen deprivation in combination with high-dose conformal radiotherapy in intermediate and high risk localized prostate cancer. https://www.astro.org/uploadedFiles/Main_Site/News_and_Media/Media_Resources/Press_Kits/Annual_Meeting_2014/Zapatero%20Slides_Formatted_v5.pdf. Accessed 15 Dec 2015

39.

Nabid A, Carrier N, Martin A-G, Bahary J-P, Souhami L, Duclos M, Vincent F, Vass S, Bahoric B, Archambault R (2013) Duration of androgen deprivation therapy in high-risk prostate cancer: a randomized trial. In: ASCO Annual Meeting Proceedings. vol 18_suppl. p LBA4510

40.

Zumsteg ZS, Spratt DE, Pei I, Zhang Z, Yamada Y, Kollmeier M, Zelefsky MJ (2013) A new risk classification system for therapeutic decision making with intermediate-risk prostate cancer patients undergoing dose-escalated external-beam radiation therapy. Eur Urol 64:895–902. doi:10.1016/j.eururo.2013.03.033CrossRefPubMed

Titel: Consensus and differences in primary radiotherapy for localized and locally advanced prostate cancer in Switzerland
A survey on patterns of practice
verfasst von: Cédric M. Panje, M.D.
Alan Dal Pra, M.D.
Thomas Zilli, M.D.
Daniel R. Zwahlen, M.D., M.B.A.
Alexandros Papachristofilou, M.D.
Fernanda G. Herrera, M.D.
Oscar Matzinger, M.D. P.D.
Ludwig Plasswilm, M.D.
Paul Martin Putora, M.D. Ph.D. M.A.
Publikationsdatum: 01.10.2015
Verlag: Springer Berlin Heidelberg
Erschienen in: Strahlentherapie und Onkologie / Ausgabe 10/2015
Print ISSN: 0179-7158
Elektronische ISSN: 1439-099X
DOI: https://doi.org/10.1007/s00066-015-0849-8

Neu im Fachgebiet Onkologie

18.04.2024 | Wirbelsäulenmetastase | Nachrichten

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Consensus and differences in primary radiotherapy for localized and locally advanced prostate cancer in Switzerland

A survey on patterns of practice

Abstract

Introduction

Materials and methods

Results

Conclusion

Neu im Fachgebiet Onkologie

Stereotaktische Radiatio schlägt konventionelle Bestrahlung

Adjuvante Brustkrebstherapie: Doppelt hält besser

Manche Gestagene können das Risiko für Meningeome erhöhen

Einladung zum PSA-Screening senkt die Krebssterblichkeit

Update Onkologie

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Abstract

Introduction

Materials and methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 10/2015

Radiation-induced camptocormia and dropped head syndrome

TH-302 – ein neues unter Hypoxie aktiviertes Zytostatikum beim Pankreaskarzinom

Three linked nomograms for predicting biochemical failure in prostate cancer treated with radiotherapy plus androgen deprivation therapy

Elective pelvic versus prostate bed-only salvage radiotherapy following radical prostatectomy

Vergleich unterschiedlicher Fraktionsdosen bei der Einzeitbestrahlung schmerzhafter Knochenmetastasen

PSA bounce after 125I-brachytherapy for prostate cancer as a favorable prognosticator

Neu im Fachgebiet Onkologie

Stereotaktische Radiatio schlägt konventionelle Bestrahlung

Adjuvante Brustkrebstherapie: Doppelt hält besser

Manche Gestagene können das Risiko für Meningeome erhöhen

Einladung zum PSA-Screening senkt die Krebssterblichkeit

Update Onkologie